Axogen Inc vs Constellation Energy Corporation — how do they compare? Axogen Inc trades at $49.28 (market cap $2.61B), while Constellation Energy Corporation trades at $278.87 (market cap $98.63B). The key difference: Constellation Energy Corporation is far larger — about 37.8× Axogen Inc's market cap, and Constellation Energy Corporation pays a 0.61% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | CEG | |
|---|---|---|
Market Cap | $2.61B | $98.63B |
Sector | Technology | Energy |
52-Week High | $48.48 | $403.95 |
52-Week Low | $14.16 | $236.50 |
Enterprise Value | $2.52B | $122.63B |
Dividend Yield | — | 0.61% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
Constellation Energy (CEG) trades at $279.75, up 3.45% in the past 24 hours, with a bullish technical signal and strong support near $277. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and new contracts like the Walmart PPA. Revenue growth is robust, with 2026 projections at $31.3 billion, and profitability metrics show a net margin of 11.08% and ROE of 15.26%.
The outlook is positive, with a consensus price target of $332.13 implying 19% upside, supported by AI-driven electricity demand and nuclear fleet advantages. Risks include execution challenges in integrating acquisitions and potential regulatory shifts. Analysts are bullish, with 70% buy ratings, citing long-term growth from data center power needs.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →